HYPR — Hyperfine, Inc.

Summary of Hyperfine Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 Revenue: $5.3 million, a 128% increase from $2.3 million in Q4 2024.
• Full Year Revenue: $13.6 million, up 5% from $12.9 million in 2024, with a significant second-half surge ($8.7 million vs. $4.8 million).
• Gross Profit: Q4 gross profit was $2.7 million (50.9% gross margin), a 226% increase year-over-year. Full year gross profit was $6.8 million (49.8% gross margin).
• Net Loss: Q4 net loss was $5.9 million ($0.06 per share), improved from a loss of $10.4 million in Q4 2024. Full year net loss was $35.6 million ($0.43 per share), down from $40.7 million in 2024.
• Cash Position: Ended Q4 with $35.1 million in cash and equivalents, extending cash runway into 2028.

2. Strategic Updates and Business Highlights

• Product Developments: Successful launch of the next-generation Swoop system and Optive AI software, enhancing image quality and clinical utility.
• Market Expansion: FDA clearance for the Swoop system in India and introduction of Optive AI software in 10 European languages.
• Clinical Validation: Positive feedback from neurology and emergency departments, with published studies supporting the Swoop system's effectiveness in stroke triage.
• Sales Growth: Sold 16 units in Q4 2025, up from 9 units in Q4 2024, with strong demand across hospitals and neurology offices.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue between $20 million to $22 million, representing a 55% year-over-year growth at the midpoint.
• Gross Margin Expectation: Anticipated gross margin of 50% to 55% for 2026, with expectations for improvement in the second half of the year.
• Cash Burn Projection: Expected cash burn of $26 million to $28 million for 2026, a 10% decline from 2025.

4. Bad News, Challenges, or Points of Concern

• Sales Variability: Larger deals may create quarterly variability due to budget cycles and procurement processes, potentially impacting revenue consistency.
• Service Revenue Decline: Lower service revenue in Q4 attributed to accounting adjustments related to technology upgrades, raising concerns about future service revenue growth.
• Market Competition: While the Swoop system has gained traction, the competitive landscape in medical imaging remains a concern as new technologies emerge.

5. Notable Q&A Insights

• Pipeline Strength: Management confirmed a robust and diversified pipeline, with significant IDN deals in progress, although these may take time to materialize due to budgetary processes.
• Pricing Strategy: The MSRP for the next-generation Swoop system increased to $590,000, which is expected to enhance ROI for hospitals, making the offering more attractive.
• Service Revenue Trajectory: Future growth in service revenue is anticipated, despite a temporary decline in Q4, as more devices are deployed and operationalized.

Overall, Hyperfine's Q4 2025 results reflect strong revenue growth and strategic advancements, though challenges related to sales variability and service revenue remain. The company is optimistic about its future trajectory, supported by a solid pipeline and ongoing product innovations.